Patents by Inventor Barbara TESTONI

Barbara TESTONI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20240150758
    Abstract: The present invention relates to a FUBPI inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBPI inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBPI and capable of reducing a FUBPI mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: June 23, 2023
    Publication date: May 9, 2024
    Inventors: Souphalone LUANGSAY, Barbara TESTONI, Fabien ZOULIM, Soren OTTOSEN, Lykke PEDERSEN
  • Use of FUBP1 inhibitors for treating hepatitis B virus infection
    Patent number: 11732262
    Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 22, 2023
    Inventors: Souphalone Luangsay, Barbara Testoni, Fabien Zoulim, Soren Ottosen, Lykke Pedersen
  • Inhibitor for use for preventing and/or treating an infection with hepatitis B virus
    Patent number: 11555191
    Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 17, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, CENTRE LÉON-BÉRARD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ CLAUDE BERNARD LYON 1
    Inventors: Jean Pierre Quivy, Barbara Testoni, Fabien Zoulim, Maelle Locatelli
  • USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20210024934
    Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 28, 2021
    Inventors: Souphalone LUANGSAY, Barbara TESTONI, Fabien ZOULIM, Soren OTTOSEN, Lykke PEDERSEN
  • AN INHIBITOR FOR USE FOR PREVENTING AND/OR TREATING AN INFECTION WITH HEPATITIS B VIRUS
    Publication number: 20200377892
    Abstract: The present invention concerns an inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus. Inventors show that the knock-down of histone chaperone HIRA before HBV inoculation led to a strong decrease in HBV cccDNA (covalently closed circular DNA) accumulation and stable rcDNA (relaxed circular DNA) levels, in HepG2-NTCP cell line, indicating either a possible incomplete or delayed rcDNA to cccDNA transition. This effect was independent from HBx protein expression in Primary human hepatocytes (PHH). HIRA is able to interact with cccDNA and its recruitment is concomitant with deposition of histone variant H3.3 in HepG2-NTCP cell line. HIRA was able to interact with HBc (HBV capsid protein) in infected hepatocytes and in an HepaRG cell line expressing HBc in an inducible manner.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 3, 2020
    Inventors: Jean Pierre QUIVY, Barbara TESTONI, Fabien ZOULIM, Maelle LOCATELLI